Advertisement
LCTX vs MDGL
Which Stock Would AI Choose? Lineage Cell Therapeutics (LCTX) vs. Madrigal Pharmaceuticals (MDGL) Stock Comparison
Key Takeaways
- LCTX is a clinical-stage cell therapy developer, while MDGL is a commercial-stage biopharmaceutical company with a blockbuster product already on the market.
- Madrigal's Rezdiffra surpassed $1 billion in year-to-date net sales in 2026, while Lineage's revenue remains modest and tied largely to milestone and collaboration payments.
- Both stocks have pulled back in recent weeks, though for very different reasons: MDGL faces a whistleblower-related overhang, while LCTX remains a high-beta, speculative early-stage name.
- Tickeron AI Verdict: MDGL is the favored ticker, reflecting its revenue generation, commercial traction, and comparatively stronger market positioning.
- For more detail on each company, explore LCTX Major News and LCTX Today's Price Move, as well as MDGL Major News and MDGL Today's Price Move.
- To see how automated strategies are trading names like these, explore Trending AI Robots.
Introduction
Investors and traders evaluating the biotechnology sector often encounter two very different kinds of opportunity: an early-stage developer betting on a future pipeline, and a commercial-stage company already generating meaningful revenue. This stock comparison places LCTX, a clinical-stage cell therapy company, alongside MDGL, a biopharmaceutical leader with an approved, revenue-generating product. The relative performance of these two names offers a useful lens on risk tolerance, market positioning, and momentum. Growth-oriented traders may find the comparison relevant for gauging how the market currently rewards commercial traction versus pipeline potential in a volatile biotech landscape.
LCTX Overview and Recent Performance
LCTX (Lineage Cell Therapeutics) is a clinical-stage biotechnology company developing allogeneic, or "off-the-shelf," cell replacement therapies. Its most visible programs include OpRegen, a retinal pigment epithelium therapy for geographic atrophy secondary to age-related macular degeneration (a form of progressive vision loss) that is partnered with Roche/Genentech, and OPC1, a cell therapy for cervical spinal cord injury. The company has also advanced earlier-stage initiatives in hearing loss (ReSonance), corneal endothelial disease (COR1), and an islet cell program targeting Type 1 diabetes.
In recent market activity, LCTX has traded near the lower end of its 52-week range, with a market capitalization in the hundreds of millions of dollars and a share price around the low single digits. Sentiment has been shaped by pipeline updates, including a ReSonance program update and the issuance of a U.S. patent covering its AlloSCOPE manufacturing platform. Sell-side coverage remains constructive, with a consensus "Strong Buy" rating and an average price target well above the current share price, though the stock's elevated beta (a measure of volatility relative to the broader market) underscores its speculative character.
MDGL Overview and Recent Performance
MDGL (Madrigal Pharmaceuticals) is a commercial-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its product, Rezdiffra (resmetirom), was the first therapy approved by both the U.S. Food and Drug Administration (FDA) and the European Commission for MASH with moderate to advanced liver fibrosis. The drug has driven rapid top-line growth, with year-to-date net sales surpassing $1 billion in 2026 and third-quarter net sales growing roughly 50% year over year to approximately $431 million.
Despite strong commercial execution, MDGL shares have eased in recent weeks, trading well below prior highs. A notable overhang emerged from a whistleblower lawsuit filed by a former senior executive alleging safety and data-integrity concerns related to Rezdiffra; the company has said it intends to defend itself vigorously, and some analysts have noted no outsized liver-safety signal in their own reviews. Broader sentiment remains shaped by the product's blockbuster trajectory, patent protection extending to 2045, and an expanding pipeline, balanced against the litigation and elevated operating expenses.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that trade thousands of different tickers, each configured with distinct trading styles, strategies, timeframes, performance statistics, and sets of tickers. Rather than showcasing every bot, Tickeron curates a focused Trending AI Robots section reserved for the strategies best suited to current market conditions. This curated view helps traders quickly identify automated approaches that align with prevailing volatility and trend regimes, rather than sifting through a lengthy list of options. If you are interested in how algorithmic strategies are positioning across names like LCTX and MDGL, exploring Trending AI Robots can offer a practical starting point.
Head-to-Head Comparison
The contrast between these two companies is fundamentally about stage and scale. MDGL operates a commercial business with an approved drug, recurring product sales, and a multi-billion-dollar market position, giving it a more predictable revenue base and stronger cash position (roughly $839 million in cash and marketable securities as of mid-2026). LCTX, by contrast, generates comparatively modest revenue from collaborations and remains dependent on clinical milestones and partnership economics, making it inherently more reliant on future catalysts.
Their risk profiles also diverge. LCTX carries clinical, regulatory, and financing risk typical of an early-stage biotech, amplified by its higher beta. MDGL carries commercial execution risk, a single-product concentration, and now litigation risk tied to the whistleblower complaint. In terms of sector exposure, both sit within healthcare, but LCTX skews toward regenerative medicine, while MDGL competes in the large and growing metabolic/liver-disease market. On momentum, both names have declined in the recent period, leaving near-term trend signals mixed for each.
Tickeron AI Verdict
Based on observable factors such as revenue generation, commercial traction, balance-sheet strength, and relative market positioning, Tickeron's AI would likely favor MDGL in this comparison. A commercial-stage company with a blockbuster product and expanding market share tends to offer more consistent, quantifiable fundamentals than a clinical-stage developer whose valuation rests heavily on future trial outcomes. That said, MDGL is not without near-term risk, particularly the litigation overhang and recent price softness, while LCTX retains meaningful upside potential if its pipeline milestones are met. The verdict reflects a probabilistic assessment of relative stability and positioning rather than a definitive forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LCTX is a Hold and MDGL is a StrongBuy.
Momentum Indicator for LCTX turns positive, indicating new upward trend
LCTX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 118 similar instances where the indicator turned positive. In 102 of the 118 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LCTX just turned positive on October 08, 2026. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.
LCTX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 159 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
LCTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.498). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MDGL's RSI Indicator ascends from oversold territory
The RSI Oscillator for MDGL moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 27 of the 33 cases the stock moved higher. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 65 cases where MDGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on MDGL as a result. In 68 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for MDGL just turned positive on November 09, 2026. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for MDGL moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MDGL entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.630) is normal, around the industry mean (3.498). P/E Ratio (-28.565) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MDGL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
LCTX | MDGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 25 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 61 | 72 | |
P/E GROWTH RATING 1..100 | 34 | 17 | |
SEASONALITY SCORE 1..100 | 90 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDGL's Valuation (15) in the Pharmaceuticals Other industry is in the same range as LCTX (26) in the null industry. This means that MDGL’s stock grew similarly to LCTX’s over the last 12 months.
MDGL's Profit vs Risk Rating (25) in the Pharmaceuticals Other industry is significantly better than the same rating for LCTX (100) in the null industry. This means that MDGL’s stock grew significantly faster than LCTX’s over the last 12 months.
MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as LCTX (98) in the null industry. This means that MDGL’s stock grew similarly to LCTX’s over the last 12 months.
LCTX's Price Growth Rating (61) in the null industry is in the same range as MDGL (72) in the Pharmaceuticals Other industry. This means that LCTX’s stock grew similarly to MDGL’s over the last 12 months.
MDGL's P/E Growth Rating (17) in the Pharmaceuticals Other industry is in the same range as LCTX (34) in the null industry. This means that MDGL’s stock grew similarly to LCTX’s over the last 12 months.
| LCTX | MDGL | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 76% |
| MACD ODDS (%) | 3 days ago 76% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 77% |
| Advances ODDS (%) | 3 days ago 76% | 16 days ago 75% |
| Declines ODDS (%) | 13 days ago 83% | 6 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LCTX’s FA Score shows that 1 FA rating(s) are green while MDGL’s FA Score has 3 green FA rating(s).
- LCTX’s FA Score: 1 green, 4 red.
- MDGL’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LCTX’s TA Score shows that 6 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).
- LCTX’s TA Score: 6 bullish, 3 bearish.
- MDGL’s TA Score: 5 bullish, 3 bearish.
Price Growth
LCTX (@Biotechnology) experienced а +2.97% price change this week, while MDGL (@Biotechnology) price change was +9.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
LCTX is expected to report earnings on Nov 12, 2026.
MDGL is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LCTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with EDIT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
|---|---|---|---|---|
| LCTX | 100% | +6.73% | ||
| EDIT - LCTX | 44% Loosely correlated | -4.99% | ||
| MDGL - LCTX | 43% Loosely correlated | +0.10% | ||
| IMNM - LCTX | 41% Loosely correlated | +2.25% | ||
| FHTX - LCTX | 41% Loosely correlated | +10.00% | ||
| VIR - LCTX | 40% Loosely correlated | -0.15% | ||
More | ||||
MDGL and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.
| Ticker / NAME | Correlation To MDGL | 1D Price Change % | ||
|---|---|---|---|---|
| MDGL | 100% | +0.10% | ||
| ALXO - MDGL | 56% Loosely correlated | +0.90% | ||
| LCTX - MDGL | 43% Loosely correlated | +6.73% | ||
| CVM - MDGL | 43% Loosely correlated | -7.09% | ||
| VOR - MDGL | 42% Loosely correlated | +2.71% | ||
| CLLS - MDGL | 40% Loosely correlated | +24.32% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| YNOT | 29.41 | 0.95 | +3.35% |
| Horizon Digital Frontier ETF (YNOT) | |||
| JGRO | 90.12 | 1.73 | +1.96% |
| JPMorgan Active Growth ETF (JGRO) | |||
| GRNI | 19.83 | 0.34 | +1.74% |
| Fundstrat Granny Shots Us Large Cap & Income ETF | |||
| XLBI | 23.53 | 0.06 | +0.24% |
| State Street Materials Select Sector SPDR Premium Income ETF (XLBI) | |||
| BHK | 8.45 | -0.04 | -0.47% |
| Blackrock Core BD TR | |||